EL7.AI
StocksMediumUpdated×2•Originally published 7 September 2026•Updated 8 September 2026•
2 min read

Novo Nordisk: 40.4% of Children Aged 6 to Under 12 Left the Obesity Range After 68 Weeks

Key Facts

1After 68 weeks, 40.4% of semaglutide recipients moved below the obesity threshold versus 0% on placebo, under an estimand assuming adherence.
2The phase 3 STEP Young trial included about 165 children aged 6 to under 12.
3The maximum weekly dose was 1.7 mg or 2.4 mg, based on starting weight.
4More than 85% of participants had class 2 or class 3 severe obesity at baseline.
5The current American label covers patients with obesity aged 12 and older and does not establish Wegovy injection for weight management below age 12.

Novo Nordisk said on September 7, 2026, that 40.4% of children with obesity aged 6 to under 12 who received semaglutide plus lifestyle modification moved below the obesity threshold for body mass index after 68 weeks, compared with 0% in the placebo group. The 40.4% rate uses an estimand that assumes all children adhered to treatment.

The phase 3 STEP Young trial included about 165 children and was multinational, randomized, double-blind and placebo-controlled. Both groups followed a reduced-calorie diet and increased physical activity, while the treatment group received once-weekly semaglutide at a maximum dose of 1.7 mg or 2.4 mg, based on starting weight.

Novo Nordisk said the trial met its primary endpoint by producing a greater reduction in body mass index with semaglutide than with placebo at week 68. More than 85% of participants had class 2 or class 3 severe obesity at baseline.

The outcome classification used age- and sex-specific growth charts. Pediatric obesity was defined as a body mass index at or above the 95th percentile, while class 2 and class 3 severe obesity began at 120% and 140% of the 95th percentile, respectively.

Novo Nordisk said safety and tolerability were consistent with earlier pediatric and adult trials of semaglutide and liraglutide, with no new safety concerns or signals involving growth or pubertal development. These remain initial company-reported results, with detailed findings due at ObesityWeek 2026 in Washington from November 14 to 17, 2026.

On the regulatory side, the current American label authorizes Wegovy injection for reducing and maintaining body weight in patients with obesity aged 12 and older, while safety and effectiveness for this use have not been established below age 12. The STEP Young results therefore do not themselves expand the authorized age group; detailed data and subsequent regulatory review remain necessary for any indication change.

Latest Updates · 1

  1. Notable·

    Update: Detailed study data revealed that the 40.4% success rate specifically refers to children who are no longer classified as having clinical obesity. These clinical results were achieved over a precise 68-week treatment and observation period, providing a specific timeframe for semaglutide's efficacy in younger populations.

Open on chart